{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078077","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.170882+00:00","generated_at":"2026-05-17T13:07:06.982784+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Leap Therapeutics Q2 net loss $16.6M, cuts workforce 75%, explores strategic alternatives","bullets":["Net loss of $16.6M for Q2 2025 vs $20.4M in Q2 2024; cash and equivalents $18.1M at June 30, 2025.","R&D expenses $10.5M (down from $17.9M); G&A $1.8M (down from $3.4M); restructuring charge $4.5M.","Board initiated review of strategic alternatives; engaged Raymond James as financial advisor.","Workforce reduced ~75% to preserve capital; majority of severance costs in Q3/Q4 2025.","Updated Phase 2 DeFianCe data showed statistically significant benefit on ORR and PFS in certain CRC subgroups."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078077","json":"https://secwatch.observer/filing/0001104659-25-078077.json","markdown":"https://secwatch.observer/filing/0001104659-25-078077.md","text":"https://secwatch.observer/filing/0001104659-25-078077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925078077/0001104659-25-078077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925078077/tm2523408d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:07:06.982784+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}